
[Expand/Collapse all sections]Expand all

This document outlines details about PBS-subsidised biological agents
for patients with severe asthma.

Asthma and listing dates

Asthma is a common long-term inflammatory disease of the airways of the
lungs.

Different biological agents require different blood results in order to
treat different types of severe asthma.

Listings dates:

-   omalizumab - 1 July 2011
-   mepolizumab - 1 January 2017
-   benralizumab - 1 December 2018
-   dupilumab - 1 April 2021

See Written Authority Required Drugs for more details.

Treatment specifics

Treatment with dupilumab 200mg or 300mg:

-   swapping from 200mg to 300 mg strength is not permitted within the
    continuing phase of the treatment. This is due to the respective
    strengths are PBS approved for different patient cohorts
-   patients on 300mg can lower the dose to 200mg as continuing
    treatment

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains:

-   PBS asthma restriction and item codes
-   ACQ-5 assessment form, and other forms
-   contact details
-   Services Australia and external website links

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
